Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pyxis Oncology, Inc. - Common Stock (NQ: PYXS )

1.670 -0.020 (-1.18%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 714,433
Open 1.610
Bid (Size) 1.630 (1)
Ask (Size) 1.670 (5)
Prev. Close 1.690
Today's Range 1.580 - 1.690
52wk Range 1.490 - 6.850
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Pyxis Oncology's Deprioritizes Second Pipeline Asset, Analyst Applauds Move
Pyxis Oncology prioritizes PYX-201 with promising Phase 1 results in solid tumors, while deprioritizing PYX-106 due to resource allocation and challenges. 
Via Benzinga
Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201
From Pyxis Oncology
Via GlobeNewswire

Performance

YTD
-18.93%
-18.93%
1 Month
-11.64%
-11.64%
3 Month
-53.61%
-53.61%
6 Month
-47.65%
-47.65%
1 Year
-4.02%
-4.02%

More News

Read More
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Nasdaq Edges Higher; Baidu Shares Fall After Q3 Results
Via Benzinga
Crude Oil Gains 1%; Deere Posts Better-Than-Expected Earnings
Via Benzinga
Exposures Fossil Fuels
Dow Jumps Over 100 Points; Nvidia Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns
Via Benzinga
Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology to Host In-Person (NYC) and Virtual Investor Event on Wednesday, November 20, 2024, to Present Preliminary Data from the Phase 1 Dose Escalation Trial of PYX-201
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology's Cancer Drug Platform Shows Potential, Analyst Sees Over 190% Upside
Via Benzinga
Pyxis Oncology to Participate in Two Upcoming Investor Conferences
From Pyxis Oncology
Via GlobeNewswire
PYXS Stock Earnings: Pyxis Oncology Misses EPS for Q2 2024
Via InvestorPlace
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology to Participate in the BTIG Virtual Biotechnology Conference
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
From Pyxis Oncology
Via GlobeNewswire
PYXS Stock Earnings: Pyxis Oncology Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference
From Pyxis Oncology
Via GlobeNewswire
Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Exposures Glyphosate
Signet Jewelers, Dave & Buster's Entertainment, Blue Owl Capital And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Topics Stocks
Exposures US Equities
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pyxis Oncology
Via GlobeNewswire
3 Biotech Stocks to Buy on the Dip: March 2024
Via InvestorPlace
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.